Consequently, whereas the dependency on CD8+ T cell activity of the secondary anti-tumor response is a phenomenon that we observed in the BP melanoma model, it is possible that other mechanisms apply to other tumors, such as KP sarcomas in which the mutational load is low. The gene discussed is CD8A; the disease is sarcoma.